Evotec stock
Price history
−51.58% over the period1 year: from €5.18 (November 20, 2025) to €2.51 (November 20, 2026), −51.58%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €2.51 |
| October 30, 2026 | €2.82 |
| September 30, 2026 | €3.10 |
| August 31, 2026 | €3.25 |
| July 31, 2026 | €3.41 |
| June 30, 2026 | €5.00 |
| May 29, 2026 | €5.28 |
| April 30, 2026 | €5.24 |
| March 31, 2026 | €4.29 |
| February 27, 2026 | €5.88 |
| January 30, 2026 | €6.22 |
| December 30, 2025 | €5.45 |
| November 28, 2025 | €5.80 |
| November 20, 2025 | €5.18 |
At a glance
The company
Develop and discover pharmaceutical products across oncology, autoimmune, cardiometabolic, CNS and rare diseases through R&D and biologics platforms
Latest results
Quarter to September 30, 2026 · EPS -€0.15 (estimate -€0.47)
TickerLandia's take on Evotec
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−62.76% from the 52-week high
Analysts · 8 analysts
Average target€3.75+49.64% vs. price
Buy 3 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Evotec
Compared with similar companies: very low profitability, very low price, and very weak momentum.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low3
How much it costs relative to what it produces.
Metric Value Position in group Price/book 0.82 4 Price/sales 0.73 1 Profitabilityvery low2
How much it earns on revenue and capital.
Metric Value Position in group Operating margin −18.0% 1 Gross margin 10.3% 4 Net margin −25.2% 1 ROA −4.9% 1 ROE −25.1% 4 Earnings stabilityvery low8
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.0% 14 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 1 Growthvery low20
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −39.80% 24 Revenue growth (year over year) +0.60% 15 Average revenue growth (3 years) +1.61% 20 Financial strengthlow23
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.32 55 Debt/equitycounts in reverse: lower means more financial strength 0.75 20 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.34 12 Interest coverage −4.57 4 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak3
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −21.77% 8 Relative strength (6 months) −48.99% 2 1-year return −51.58% 2 Distance from 200-day average −39.34% 2 Riskvery high85
How much the price swings.
Metric Value Position in group Beta (1 year) 0.93 65 Volatility (60 days) 53.1% 93 Maximum drawdown (12 months) 62.7% 98
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Evotec is cheaper than similar companies
Evotec's Price/book: 0.69, −75% against the median of a group of 11 similar companies (2.83).
Compared with 11 similar companies
| Metric | Evotec | Position in the group | Band |
|---|---|---|---|
| Operating margin | -18.0% | Low | |
| ROE | -25.1% | Low | |
| Debt/equity | 0.75 | High | |
| Price/book | 0.69 | Low | |
| Net margin | -25.2% | Low |
Grey band: the middle half of the group; tick: the median; dot: Evotec. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€164.93M
Latest quarter · Q3 2026
Net income
-€26.74M
Latest quarter · Q3 2026
Quarterly net margin
-16.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €445.3M
- EPS
- -€1.01
- Volume
- 2.79M
- Daily trading
- €3.3M
- Dividend yield
- 0.00%
How Evotec is changing
All resultsRevenue grew 9.5% a year on average over the last 5 years
Operating margin fell from 2.8% to −8.4%
Shares outstanding up 14.6% in 5 years
Returns
Evotec returns
€1,000 invested in Evotec 5 years ago, on November 22, 2021, would be worth €59 today: −94.14% in total, −43.34% per year. This is the price return only: dividends are excluded.
| Period | Evotec | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | −7.94% | −1.98% | €921 |
| 6 months | −48.86% | +0.26% | €511 |
| Year to date | −54.02% | +1.28% | €460 |
| 1 year | −51.58% | +6.55% | €484 |
| 3 years | −86.96% | — | €130 |
| 5 years | −94.14% | — | €59 |
| 10 years | −58.90% | — | €411 |
Over the last 6 months it has done better than 2% of the stocks in the Industrials sector.
Price only, without dividends. Calculate your investment
The chart in detail
Evotec: technical analysis
Evotec is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 97.3% below its all-time closing high (€91.95, March 3, 2000).
- Trend
- Downward
- RSI (14 sessions)
- 32
- Between 30 and 70
- vs 200-session average
- −39.34%
Active signals
Close below the low of the previous 20 sessions.
Trading on November 20, 2026 was 2.7 times the 20-session average.
Support and resistance
Price areas where Evotec has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€3.37+34.50%3 touches, last on November 9, 2026
- Resistance€3.13+25.02%4 touches, last on October 1, 2026
- Resistance€2.72+8.54%3 touches, last on November 3, 2026
- Last price€2.51
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved roughly in line with the DAX.
- Beta (1 year) vs DAX
- 0.93
- Volatility (60 sessions, annualised)
- 53.1%
- Largest fall in the last year
- −62.70%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Evotec: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Evotec has been January: +4.72% on average, positive in 16 years out of 27. The weakest has been July: −2.63% on average, positive in 9 years out of 27. November, the current month, has been positive in 12 years out of 26 (−0.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.72% | +5.47% | 16 of 27 |
| February | +2.97% | −2.57% | 10 of 27 |
| March | −2.31% | −2.29% | 12 of 27 |
| April | +3.70% | −0.05% | 13 of 27 |
| May | −0.58% | +0.75% | 14 of 27 |
| June | +1.75% | −0.49% | 12 of 27 |
| July | −2.63% | −3.04% | 9 of 27 |
| August | +3.08% | −0.09% | 13 of 27 |
| September | −2.23% | −2.97% | 11 of 27 |
| October | +2.98% | +0.49% | 15 of 27 |
| November | −0.68% | −0.19% | 12 of 26 |
| December | +0.32% | −3.31% | 11 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Evotec and its competitors
With revenue of EUR 788.4 million in the fiscal year ended December 2025, down 1.1% from the previous year, and a net loss of EUR 103.5 million, Evotec SE employed 4,379 people. The company is headquartered in Hamburg, Germany, was founded in 1993, and changed its name from Evotec AG in April 2019.
- Headquarters
- Hamburg, Germany
- Employees
- 4,379
- Founded
- 1993
- Chief executive
- Christian Wojczewski
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| EvotecEVT | $489.39M | -18.0% | — | −48.86% |
| PharmaNutraPHN | $917.61M | 22.0% | 36.7 | −2.50% |
| Faes FarmaFAE | $1.65B | 13.0% | 17.9 | +4.66% |
| FagronFAGR | $1.97B | 14.3% | 19.5 | −0.20% |
| AlmirallALM | $2.45B | 9.6% | 30.2 | −9.84% |
| Siegfried HoldingSFZN | $3.4B | 16.7% | 16.7 | −19.46% |
Same industry or related industries, similar size. Compare Evotec with its competitors · Full profile
